SCHEMBL3037553

SCHEMBL3037553

O=c1nc(Cl)[nH]c2cc(Cl)ccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.55
TP53 P04637 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
MAT2A P31153 5/20 0.53
LMNA P02545 3/20 0.51
CA9 Q16790 2/20 0.49
CA12 O43570 1/20 0.49
DAO P14920 1/20 0.48
HAVCR2 Q8TDQ0 1/20 0.48
HPGD P15428 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
CYP2C9 P11712 1/20 0.47
MAPK1 P28482 1/20 0.47
BLM P54132 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 2/20 0.47
GRIN2D O15399 2/20 0.47
GRIN3B O60391 2/20 0.47
GRIN1 Q05586 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30918936 1.00 PARP1 (0.55) PARP1TP53SMN1; SMN2MAT2ALMNA
SCHEMBL30918933 0.85 LMNA (0.53) PARP1LMNACA9CA12HPGD
SCHEMBL6670117 0.84 ALDH1A1 (0.59) PARP1TP53SMN1; SMN2MAT2ALMNA
SCHEMBL30918929 0.81 FEN1 (0.46) PARP1LMNADAOHPGDKDM4E
SCHEMBL578053 0.81 FEN1 (0.46) PARP1LMNADAOHPGDKDM4E
SCHEMBL1161627 0.81 PARP1 (0.47) PARP1TP53SMN1; SMN2MAT2ALMNA
SCHEMBL10275254 0.79 GUSB (0.55) PARP1TP53SMN1; SMN2MAT2ALMNA
SCHEMBL30918927 0.78 JUN (0.56) CA9CA12HPGDMEN1KMT2A
SCHEMBL6616078 0.77 TP53 (0.57) PARP1TP53SMN1; SMN2MAT2ALMNA
SCHEMBL30918930 0.76 PARP1 (0.56) PARP1SMN1; SMN2LMNACA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2396316-B1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-07-01 EP disclosed
US-8937078-B2 Quinazolinones as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-01-20 US disclosed
EP-2396316-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2011-12-21 EP disclosed
WO-2010093727-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-08-19 WO disclosed
US-20100204226-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204226-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 PARP1 637/4885TP53 3649/4885SMN1; SMN2 4163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.